CathVision launches PVI Analyzer and Signal Complexity algorithms following FDA clearance

1353

cathvisionCathVision has announced US Food and Drug Administration (FDA) clearance and commercial availability of the PVI Analyzer and Signal Complexity algorithms, part of the Cardialytics suite of artificial intelligence-powered analytics integrated into the ECGenius system.

According to a CathVision press release, the ECGenius system is now the only EP recording system with an AI algorithm to facilitate electrogram interpretation and deliver intelligent, automated analyses to help physicians improve ablation outcomes in complex atrial arrhythmia procedures by measuring the success of cardiac ablation.

PVI Analyzer is a signal-based AI algorithm capable of confirming pulmonary vein isolation (PVI) status across multiple cardiac ablation modalities when physicians treat complex arrhythmias such as atrial fibrillation (AF). Signal Complexity is intended to help physicians visualise and quantify atrial AF complexity parameters in patients with persistent AF. The tools are available to physicians using the ECGenius System on a price-per-use basis.

“CathVision’s technology has taken us back to our roots in cardiac electrophysiology and improved upon critical data that was vastly overlooked for many years,” said Larry Chinitz (NYU Langone, New York, USA). “With improved signal quality providing accurate and meaningful data, the integration of Cardialytics’ uniquely principled AI tools will continue CathVision’s transformation of electrophysiology.”

“Our mission has always been to put electrophysiologists in the best position to improve clinical outcomes. Incorporating AI-based analytics into the ECGenius System is another important demonstration of our unique ability to deliver on that mission and achieve groundbreaking milestones. With clinical enhancements exclusively available in our ECGenius system, we maintain our leadership position in equipping electrophysiologists with the technology necessary to elevate patient outcomes,” said Mads Matthiesen, CEO, CathVision. “CathVision is poised for an exciting phase as we launch the ECGenius System with Cardialytics and intensify our research endeavours to continue delivering innovative technology that simplifies processes.”


LEAVE A REPLY

Please enter your comment!
Please enter your name here